Sydney Lepkin
👤 SpeakerAppearances Over Time
Podcast Appearances
Novo Nordisk's announcement follows the Trump administration's deals with Novo Nordisk and Eli Lilly earlier this month.
The deals included lower direct-to-consumer costs of the company's blockbuster obesity drugs.
But even the discounted prices will still be too high for many patients.
The number of adults taking GLP-1 drugs, which include Ozempic, Wegovy, Zephound, and Manjaro, is going up.
It went from 6% a year and a half ago to 12% now.
People are taking the drugs for chronic conditions like type 2 diabetes and heart disease, as well as for weight loss.
Here's Ashley Kurtzinger, a pollster at KFF.
Although most people taking these drugs say they have some insurance coverage for them, more than half say the drugs are difficult to afford.
KFF conducted the poll between October 27th and November 2nd.
Normally, companies can't advertise a drug to treat a condition it hasn't been FDA-approved to treat.
But sponsored search results online aren't regulated the way television ads are.
Daniel Eisenkraft-Klein and his colleagues at Harvard Medical School looked at two years of paid search results for Ozempic.
According to a study published in JAMA Network Open, 11% of paid search phrases contain the word weight, even though Osempic is only approved to treat type 2 diabetes.
Novo Nordisk says its paid search approach is standard and in compliance with U.S.
President Trump announced drug maker EMD Sirono has agreed to lower prices for its fertility drugs, like Gonal-F, sold directly to patients not using their insurance.